| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40812 | UPSHER SMITH LABS | Nasal calcitonin formulation |
Feb, 2021
(3 years ago) | |
| USRE43580 | UPSHER SMITH LABS | Nasal calcitonin formulations |
Feb, 2021
(3 years ago) | |
| US6440392 | UPSHER SMITH LABS | Nasal calcitonin formulations |
Feb, 2021
(3 years ago) | |
Fortical is owned by Upsher Smith Labs.
Fortical contains Calcitonin Salmon Recombinant.
Fortical has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Fortical are:
- USRE40812
- USRE43580
- US6440392
Fortical was authorised for market use on 12 August, 2005.
Fortical is available in spray, metered;nasal dosage forms.
Fortical can be used as nasal administration.
The generics of Fortical are possible to be released after 02 February, 2021.
Drugs and Companies using CALCITONIN SALMON RECOMBINANT ingredient
Market Authorisation Date: 12 August, 2005
Treatment: Nasal administration
Dosage: SPRAY, METERED;NASAL
How can I launch a generic of FORTICAL before it's drug patent expiration?
More Information on Dosage
FORTICAL family patents
